Upstream Bio, Inc.’s Lock-Up Period Will Expire on April 9th (NASDAQ:UPB)

Upstream Bio’s (NASDAQ:UPB) lock-up period is set to end on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the end of the lock-up period.

Upstream Bio Stock Up 9.5 %

Shares of UPB stock opened at $6.70 on Wednesday. Upstream Bio has a 52-week low of $5.85 and a 52-week high of $29.46. The stock has a 50-day moving average price of $8.45.

Hedge Funds Weigh In On Upstream Bio

Institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets purchased a new position in Upstream Bio in the fourth quarter worth $25,000. US Bancorp DE bought a new stake in shares of Upstream Bio during the 4th quarter worth $27,000. Legal & General Group Plc purchased a new position in shares of Upstream Bio in the 4th quarter worth about $28,000. Summit Investment Advisors Inc. purchased a new position in shares of Upstream Bio in the 4th quarter worth about $30,000. Finally, Tower Research Capital LLC TRC bought a new position in Upstream Bio during the fourth quarter valued at about $47,000.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.